# Evaluation of Sentinel Lymph Nodes in Head and Neck Squamous Cell Carcinoma

Source: https://onco.cc/trials/nct00911326/  
OnCo record `nct00911326` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Technetium-99m tilmanocept in Head and neck squamous cell carcinoma, run by Navidea Biopharmaceuticals, recorded as terminated on the registry.

## Summary

Evaluation of Sentinel Lymph Nodes in Head and Neck Squamous Cell Carcinoma is a phase 3 interventional study registered as NCT00911326 by Navidea Biopharmaceuticals, with 101 participants recorded, started 2009-05 and due to reach its primary completion in 2013-08. Interventions recorded: Lymphoseek. Conditions recorded: Head and Neck Squamous Cell Carcinoma (HNSCC).

Linked to the drug Technetium-99m tilmanocept because the registry names it among its interventions and Head and neck squamous cell carcinoma among its conditions. Registry record only: no result has been read by an editor.

## Fields

- Kind: Trial
- Last checked: 2026-09-22
- Tags: pipeline; ctgov-ingest
- Registry id: NCT00911326
- Phase: 3
- Setting: A Ph 3, Prospective, Open-Label, Multicenter Study of Lymphoseek®-Identified Sentinel Lymph Nodes (SLNs) Relative to the Path Status of Non SLN in an Elective Neck Dissection in Cutaneous Head and Neck and Intraoral Squamous Cell Carcinoma
- Sponsor: Navidea Biopharmaceuticals
- Enrolled: 101

## Sources

- ClinicalTrials.gov NCT00911326: https://clinicaltrials.gov/study/NCT00911326

## Connected records

- cancers: [Head and neck squamous cell carcinoma](https://onco.cc/cancers/head-and-neck/)
- drugs: [Technetium-99m tilmanocept](https://onco.cc/drugs/tilmanocept-tc99m/)
- companies: [Navidea Biopharmaceuticals](https://onco.cc/companies/navidea/)

---
JSON: https://onco.cc/api/v1/entities/nct00911326.json